For pediatric nonoperative fractures and sprains, adding acetaminophen or hydromorphone to ibuprofen does not provide better ...

Dr. Edward Paul answers the question: 'How Does Chronic Pain Differ From Acute?' — -- Question: What Is Chronic Pain And How Does It Differ From Acute Pain? Answer: Chronic pain and acute pain ...

LTG-001 demonstrated rapid absorption with a Tmax of approximately 1.5 hours. The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain.

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

Pain has the potential to affect various aspects of a person’s life, from disrupting one’s daily routine to negatively impacting emotional well-being. It’s also one of the most common reasons that ...

Immediate pain reductions were noted among patients in the ED after receiving acupuncture for acute musculoskeletal pain.

Editor’s Note (1/31/25): The U.S. Food and Drug Administration has approved the novel nonopioid medication suzetrigine for acute pain. That pain ranges from moderate to severe. The drug was tested in ...

The FDA approved prescription suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults, the agency announced Thursday.

With the world in an opioid crisis, the development of non-opioid analgesics has become more urgent. A series of Phase 3 clinical trials into a novel oral, non-opioid painkiller has found that it’s ...

A patient with Poland syndrome presents with acute pericarditis, underscoring diagnostic hurdles in chest pain due to ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...